瑞舒伐他汀对不稳定型心绞痛患者支架术后炎性因子的影响

目的：探讨瑞舒伐他汀对不稳定型心绞痛患者（UA）冠脉支架植入（PCI）术后血清妊娠相关蛋白-A（PAPP-A）和肿瘤坏死因子α（TNF-α）的影响。方法：选取2011年8月-2013年10月本院心内科住院的110例UA患者,按照随机数字表法将其分为瑞舒伐他汀20 mg治疗组（高剂量组）和10 mg治疗组（低剂量组）各55例,另选取正常对照组100例。测定各组入院时及术后1周/1个月PAPP-A及TNF-α水平。结果：PCI术前UA两组血清PAPP-A和TNF-α水平均明显高于对照组,差异均有统计学意义（P〈0.01）；术前高剂量组和低剂量组的PAPP-A及TNF-α水平比较差异无统计学意义（P〉0.05）。PCI术后1周UA两组的PAPP-A及TNF-α水平均明显低于术前（P〈0.01）,但仍高于正常对照组（P〈0.01）；PCI术后1个月UA两组的血清PAPP-A及TNF-α水平与正常对照组相比较差异均无统计学意义（P〉0.05）,但高剂量组与低剂量组相比较差异均有统计学意义（P〈0.05）。结论：瑞舒伐他汀可以降低UA患者PCI术后PAPP-A及TNF-α的浓度,减轻炎症反应,稳定冠脉粥样硬化斑块。

Effects of Rosuvastatain in Therapy on Serum Inflammatory factors after Percutaneous Coronary Intervention in Patients with Unstable Angina

Objective：To investigate the effects of rosuvastatain in therapy on serum PPAP-A,TNF-αlevels after percutaneous coronary intervention（PCI） in patients with unstable angina（UA）.Method：110 patients with UA in our cardiology department from August 2011 to October 2013 were selected,they were randomly divided into the high-dose group and the low-dose group,55 cases in each group.The high-dose group was treated with rosuvastatain 20 mg every day before and after PCI.The low-dose group was treated with rosuvastatain 10 mg every day.100 cases were selected as normal control group.The levels of PAPP-A and TNF-α were detected before PCI and at 1 week,1 month after PCI.Result：The levels of PAPP-A and TNF-α in two UA groups were significantly higher than those in the control group before PCI,the differences were statistically significant（P〈0.01）.Compared with low-dose group,the levels of PAPP-A and TNF-α in high-dose group were no significance before PCI（P〉0.05）.The levels of PAPP-A and TNF-α decreased at 1week and 1month after PCI in UA two groups （P〈0.01）.One week after PCI,the levels of PAPP-A and TNF-α in rosuvastatain in high-dose group and low-dose group were significantly higher than those in the control group（P〈0.01）.One month after PCI,the levels of inflammatory factors were no difference between UA two groups and control group（P〉0.05）.While compared with low-dose group,the values in high-dose group were lower（P〈0.05）. Conclusion：Rosuvastatain can decrease the levels of PAPP-A and TNF-α significantly in patients with UA after PCI, and it is good for the stability of atherosclerotic plaques.